Journal: Nature Communications

Article Title: Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice

doi: 10.1038/s41467-023-38141-0

Figure Lengend Snippet: a Free fatty acids (FFAs) levels in the liver of male WT mice exposed to 25 °C (RT) or 4 °C (Cold) for different amounts of time in the absence of food and water. b PREP activity in primary hepatocytes treated with 0, 0.75 or 1 mM oleic acid (OA) for different amounts of time. c BK levels in cell lysates and the culture medium of primary hepatocytes treated with 0, 0.75 or 1 mM OA for 6 h. d BK levels in cell lysates and the culture medium of primary hepatocytes infected with (+ Ad-PREP) or without (–Ad-PREP) Ad-PREP in the absence (–OA) or presence (+OA) of 1 mM OA for 6 h. e BK levels in cell lysates and the culture medium of primary hepatocytes treated with 0, 10 or 50 μg/mL S17092 for 6 h. f BK levels in cell lysates and the culture medium of primary hepatocytes transfected with (si- Prep ) or without (si-NC) Prep siRNA for 72 h. g , h PREP activity ( g ) and BK levels in cell lysates and the culture medium of primary hepatocytes ( h ) treated with (+UDCA) or without (–UDCA) ursodeoxycholic acid (UDCA) in the absence (–OA) or presence (+OA) of 1 mM OA for 6 h. For a , n = 7 in each group. For b and c , n = 4 or 5 in each group. For d , n = 4–6 in each group. For e , n = 6 in each group for hepatocytes; n = 5 (medium 0 μg/mL S17092) and 4 (medium 10 μg/mL, 50 μg/mL S17092) in each group. For f , n = 4–6 in each group. For g , n = 6 in each group. For h , n = 5 or 6 in each group for hepatocytes; n = 5 in each group for medium. Mean±SEM are representative of at least two independent experiments ( a ) or at least three independent experiments ( b–h ); two-tailed unpaired Student’s t -test ( a ), ordinary one-way ANOVA with Dunnett’s test ( b, c, e, f ), ordinary one-way ANOVA with Tukey’s test ( d ), ordinary two-way ANOVA with Tukey’s multiple comparisons test ( g, h ). Source data are provided as a Source data file.

Article Snippet: OA (Sigma, USA), s17092 (Sigma, USA) and UDCA (MCE, China) were added at the indicated concentrations in DMEM without FBS on the second day following hepatocytes isolation.

Techniques: Activity Assay, Infection, Transfection, Two Tailed Test

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Validation of the optimal working concentration and treatment of UDCA to inhibit FIPV proliferation. ( A ) CCK-8 assay for the effect of ursodeoxycholic acid on the activity of CRFK-PHBLV-N cells. ( B ) FIPV N gene level after the action of ursodeoxycholic acid. ( C ) Western blotting to detect the changes of FIPV N protein. ( D ) Gray scale of the FIPV N protein change analysis. ( E ) CRFK-PHBLV-N cells in FIPV IFA results graph. ( F ) CRFK-PHBLV-N cells in FIPV fluorescence intensity analysis. **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Biomarker Discovery, Concentration Assay, CCK-8 Assay, Activity Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in FIPV N gene copy number and protein expression at different stages after ursodeoxycholic acid treatment. ( A ) Graph of different stages of treatment. ( B ) Graph of FIPV N gene copy number results in CRFK-PHBLV-N cells at different stages. ( C ) Graph of FIPV results in CRFK-PHBLV-N cells at different stages. ( D ) Grayscale analysis of FIPV in CRFK-PHBLV-N cells at different stages. ( E ) Negative staining electron micrograph of FIPV virus particles. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; and ns, not significant.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Expressing, Negative Staining, Virus

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Screening of signaling pathways associated with anti-FIPV infection after UDCA co-treatment based on transcriptomic data. ( A ) KEGG pathway enrichment analysis. ( B ) Differential gene volcano plot. ( C ) Correlation analysis of FIPV-UDCA 200 μg/mol co-treatment with antiviral gene expression. ( D ) IFN-β ELISA results in CRFK-PHBLV-N cells. * P < 0.05; ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Protein-Protein interactions, Infection, Gene Expression, Enzyme-linked Immunosorbent Assay

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in STAT1 phosphorylation and nuclear translocation levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) STAT1 Western blot results in CRFK-PHBLV-N cells. ( B ) Grayscale analysis of p-STAT1/STAT1 protein in CRFK-PHBLV-N cells. ( C ) CRFK-STAT1 IFA results in PHBLV-N cells. ( D ) STAT1 fluorescence intensity analysis in CRFK-PHBLV-N cells. ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Phospho-proteomics, Translocation Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in TLR3 protein, IRF3 phosphorylation, and nuclear translocation levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) Graph of TLR3 and IRF3 Western blot results in CRFK-PHBLV-N cells. ( B ) Graph of TLR3 protein grayscale analysis in CRFK-PHBLV-N cells. ( C ) Grayscale analysis plot of p-IRF3/IRF3 protein in CRFK-PHBLV-N cells. ( D ) Graph of IRF3 IFA results in CRFK-PHBLV-N cells. ( E ) Graph of IRF3 fluorescence intensity analysis in CRFK-PHBLV-N cells. ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Phospho-proteomics, Translocation Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in MX1 and ISG15 protein levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) Western blot results of MX1 and ISG15 in CRFK-PHBLV-N cells. ( B ) Grayscale analysis of MX1 protein in CRFK-PHBLV-N cells. ( C ) Grayscale analysis of ISG15 protein in CRFK-PHBLV-N cells. ISG15 protein grayscale analysis graph in CRFK-PHBLV-N cells. * P < 0.05; ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Western Blot

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Diagram of UDCA anti-FIPV mechanism through JAK-STAT signaling pathway.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques:

Journal: Biology of Sex Differences

Article Title: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

doi: 10.1186/s13293-022-00473-9

Figure Lengend Snippet: Sex differences in bile acid levels by comparing stage II RCC and LCC from patients aged ≥ 55 years

Article Snippet: Ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) were purchased from ChemCruz (Santa Cruz Biotechnology, Inc., Dallas TX).

Techniques:

Journal: Biology of Sex Differences

Article Title: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

doi: 10.1186/s13293-022-00473-9

Figure Lengend Snippet: Multivariable Cox regression associating 17 bile acid levels or ratio of conjugated bile acids to unconjugated bile acids and 5-year overall survival for patients ≥ 55 years old ( n = 197) adjusting for age, sex, tumor anatomic location, stage, and chemotherapy use

Article Snippet: Ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) were purchased from ChemCruz (Santa Cruz Biotechnology, Inc., Dallas TX).

Techniques:

Journal: Biology of Sex Differences

Article Title: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

doi: 10.1186/s13293-022-00473-9

Figure Lengend Snippet: Multivariable Cox regression associating 17 bile acid abundances or ratios to 5-year recurrence-free survival (RFS) for patients ≥ 55 years old ( n = 197) adjusting for age, sex, tumor anatomic location, stage, and chemotherapy use

Article Snippet: Ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) were purchased from ChemCruz (Santa Cruz Biotechnology, Inc., Dallas TX).

Techniques:

Journal: Biology of Sex Differences

Article Title: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

doi: 10.1186/s13293-022-00473-9

Figure Lengend Snippet: Pearson correlation of glucuronic acid to bile acid abundances in patients with right-sided colon cancer ≥ 55 years old ( n = 98)

Article Snippet: Ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) were purchased from ChemCruz (Santa Cruz Biotechnology, Inc., Dallas TX).

Techniques:

Journal: Biology of Sex Differences

Article Title: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

doi: 10.1186/s13293-022-00473-9

Figure Lengend Snippet: Correlations between prognosis-linked bile acid levels and T cell abundances in tissues ( n = 10). Tumor tissues from stage II patients, 6 RCCs and 4 LCCs

Article Snippet: Ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) were purchased from ChemCruz (Santa Cruz Biotechnology, Inc., Dallas TX).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: DX-UDCA MSs elaboration. Created with BioRender.com

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Conditions studied for the formulation optimisation (A-H)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Formulation, Solvent

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Summarized conditions of the selected DX-UDCA-MSs formulation (corresponding to F formulation in the formulation optimization process), single-loaded formulations (UDCA-MSs and DX-MSs), and the incorporation of the GDNF in the optimized formulation (DX-UDCA-GDNF-MSs)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Formulation, Solvent

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: DSC curves of [ A ] PLGA (green), UDCA (red) and DX (blue), [ B ] physical mixtures of PLGA + DX (red), PLGA + UDCA (blue) and PLGA + DX + UDCA (green), [ C ] PLGA MSs (blue) and PLGA + vitamin E MSs (red), [ D ] DX MSs (blue) and UDCA MSs (black) and [ E ] DX-UDCA-MSs with different proportions of solvents 75:25 (red), 80:20 corresponding to F (blue) and 85:15 corresponding to H (green)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: X-Ray diffractograms of [ A ] the different compounds (PLGA – red, DX – blue, and UDCA – green), [ B ] physical mixtures of the compounds (PLGA + DX – blue, PLGA + UDCA – green, and PLGA + DX + UDCA – orange), [ C ] non-loaded (red) and single loaded MSs (with DX – blue, with UDCA – green) and [ D ] co-loaded DX-UDCA-MSs elaborated with different solvent mixtures (MC:EtOH) (75:25 – blue, 80:20 – red and 85:15 – green)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Solvent

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: UDCA entrapment efficiencies of the different formulations (A-H). A and B were elaborated only with methylene chloride in the inner phase of the emulsion while C-H were elaborated with different mixtures of methylene chloride and ethanol as solvent of the inner phase of the emulsion

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Emulsion, Solvent

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: 24 h UDCA and DX burst release of selected formulations (E and F)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Scanning and transmission electron microscopies pictures and particle size distribution of the selected formulation (DX-UDCA-MSs), the only loaded DX formulation (DX-MSs), the only loaded UDCA formulation (UDCA-MSs), and the selected formulation with protein included (DX-UDCA-GDNF-MSs) MSs. Individual scanning pictures were made at × 2000, and group pictures at × 500

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Transmission Assay, Formulation

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Mean particle size of the selected DX-UDCA-MSs formulation (F), the formulations with only DX or UDCA included (DX-MSs and UDCA-MSs) and the final formulation with GDNF included (DX-UDCA-GDNF-MSs)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Formulation

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Confocal microscopy images of Nile Red labelled PLGA microsphere and BSA-FITC distribution. From left to right: microspheres of formulation DX-UDCA-MSs, microspheres of formulation DX-UDCA-GDNF-MSs replacing GDNF for BSA-FITC (Nile Red channel, BSA-FITC channel, and the combination of Nile Red and BSA-FITC channels)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Confocal Microscopy, Formulation

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Entrapment efficiencies of the different active compounds (DX, UDCA, GDNF) in the mono-loaded, optimized, and final formulations

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Cumulative in vitro release (μg/mg MSs and %) of DX from DX-MSs ( A ), of UDCA from UDCA-MSs ( B ), of DX and UDCA from DX-UDCA-MSs ( C ), and of DX and UDCA from DX-UDCA-GDNF-MSs ( D )

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: In Vitro

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Release profile of GDNF from DX-UDCA-GDNF-MSs. A more detailed zoom of the release has been inserted from day 7 until the end of the study (91 days)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Values of the release model parameters in the different in vitro experiments. (Experimental B – 24-h release of experimental data –, B – burst parameter from the equation –, Y 1 and Y 2 – relative amounts of drug release in the different stages –, K 1 and K 2 – kinetic constants of the different stages –, and t 2 – characteristic time of the stage 2 where the maximum drug is released –)

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: In Vitro

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: SEM images from different degradation dates (0, 2, 4, 6, 8, and 10 weeks) of different formulations (Blank MSs, UDCA-MSs, DX-MSs, DX-UDCA-MSs and DX-UDCA-BSA-MSs) with the PLGA molecular weight. Scale bars: 10 µm

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Molecular Weight

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Intraocular pressure (IOP). Comparison of intraocular pressure curves in the four cohorts. Subanalysis by eye laterality ( A ) and by sex ( B ) in each model. *: statistical significance (p < 0.05). G: Glaucoma cohort; IV: intravitreal injection; NP: neuroprotective; DX: dexamethasone; UDCA: ursodeoxycholic acid; GDNF: glial cell line-derived neurotrophic factor

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Comparison, Injection, Derivative Assay

Journal: Drug Delivery and Translational Research

Article Title: Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

doi: 10.1007/s13346-024-01702-x

Figure Lengend Snippet: Optical coherence tomography (OCT). Comparison of retina, GCL, and pRNFL thickness in the four cohorts. A ) Subanalysis by eye laterality in each cohort. B ) Right eyes in retina and GCL protocols statistically significant in the four cohorts. C ) Subanalysis by sex in each cohort. G: Glaucoma cohort; IV: intravitreal injection; NP: neuroprotective; DX: dexamethasone; UDCA: ursodeoxycholic acid; GDNF: glial cell line-derived neurotrophic factor. Horizontal lines mean no differences between the parameters analyzed. Up arrows mean an increase in thickness of right eye vs left eye and male vs female. Down arrows mean a decrease in thickness of right eye vs left eye and male vs female

Article Snippet: Ursodeoxycholic acid (UDCA) (purity > 99%) was obtained from Alfa Aesar (Haverhill, Massachusetts, USA) and Dexamethasone (DX) (purity > 98%), DL-alpha-tocopherol acetate was provided by Sigma-Aldrich (St. Louis Mo., USA).

Techniques: Tomography, Comparison, Injection, Derivative Assay